2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Lauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses combination therapies in cutaneous T-cell lymphoma.
Lauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses combination therapies in cutaneous T-cell lymphoma (CTCL).
Combination therapies in CTCL have not been studied a great deal. There is a desire for many practicing physicians to "layer" treatments that only garner some response to prevent the disease from breaking loose, Pinter-Brown says. As a result, patients are often treated with combinations that have not been studied. There are some combination therapies that have been studied: retinoids with light, interferon with light, photopheresis with interferon, and photopheresis with retinioids.
Related Content: